| 货号 | 2839/50 |
| 别名 | (2S)-(2-Oxopyrrolidin-1-yl)butyrami |
| 供应商 | Tocris |
| 生物活性 | Antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3-exchange. |
| 运输条件 | Blue Ice |
| 存放说明 | Ambient |
| 纯度 | >99 % |
| 计算分子量 | 170.21 |
| 分子式 | C8H14N2O2 |
| 可溶性/溶解性 | Soluble to 100 mM in water and to 100 mM in DMSO |
| CAS号 | 102767-28-2 |
| 参考文献 | Smedtet al (2007) Levetiracetam: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev. 13 43. PMID: 17461889. Uedaet al (2007) Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 1151 55. PMID: 17408599. Lynchet al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proct.Natl.Acad.Sci. USA 1019861. |